Saturday, August 2, 2025 8/2/2025

Secondary Molecular Imaging (SMI) for head and neck cancer

Award Number: R01CA279249
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2024
PERIOD OF PERFORMANCE END DATE: 01/31/2029

Group Awards By:

View Award Description

Secondary Molecular Imaging (SMI) for head and neck cancer - Project Summary The current standard of care for evaluation and surveillance of regional and metastatic disease in advanced stage head and neck squamous cell carcinoma (HNSCC) is 18F-FDG-PET/CT scan, which is highly sensitive but not specific and as a result identifies a significant number of indeterminate lesions. Interrogation of these lesions leads to unnecessary procedures, overdiagnosis/upstaging, patient anxiety, increased cost, and possible treatment delays due to the need for repeat imaging. To address this, we will investigate whether PET imaging using a radiolabeled anti-EGFR antibody (89Zr-panitumumab) can be used to detect cancer with high specificity. We will use 89Zr-panitumumab PET/CT to assess HNSCC patients with indeterminate findings on 18F-FDG PET/CT and determine the positive predictive value of 89Zr- pan PET/CT for detection of metastatic disease. The nonspecific nature of 18F-FDG-PET/CT also limits its usefulness in detecting small primary tumors in patients with oropharyngeal cancer. This study will assess the effectiveness of 89Zr-pan PET/CT imaging for detecting unknown primary tumors in patients presenting with an enlarged neck node without identification of the primary tumor on exam or conventional imaging. Successful detection of the primary tumor using 89Zr-pan PET/CT would avoid the invasive biopsies typically required to locate the primary tumor in these patients. The novel imaging modality developed in this study could overcome the limitations of metabolic 18F-FDG PET/CT imaging, thereby reducing the number of invasive procedures and avoiding delays in treatment due to indeterminate findings.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $381,676 )
2025	2025	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Detection and Diagnosis Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$38,167
2025	2025	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Detection and Diagnosis Research	000	2	2/19/2025	NON-COMPETING CONTINUATION	$343,509
														Subtotal = $381,676

Issue Date FY: 2024 ( Subtotal = $338,740 )
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Detection and Diagnosis Research	000	1	2/1/2024	NEW	$338,740
														Subtotal = $338,740

Grand Total All Awards = $720,416

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Secondary Molecular Imaging (SMI) for head and neck cancer

Award Number: R01CA279249

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2024

PERIOD OF PERFORMANCE END DATE: 01/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer